GLP-1 receptor agonists for obesity: eligibility across 99 countries.
Yoo SGK, Teufel F, Theilmann M, Si Y, Toure EA, Aryal K, Bärnighausen T, Bait A, Barreto M, Bovet P, Brant LCC, Cuschieri S, Damasceno A, Farzadfar F, Fawwad A, Geldsetzer P, Hambleton IR, Houehanou C, Howitt C, J Rgensen J, González-Rivas JP, Labadarios D, Marcus M, Martins J, Mwalim O, Nieto-Martínez R, Odili AN, Orazumbekova B, Perman G, Quesnel-Crooks S, Moghaddam SS, Sewpal R, Sousa-Uva M, Sulola MA, Venkataraman K, Vollmer S, Xueling S, Atun R, Banegas JR, Franco JVA, Arnott C, Chandiwana N, Huffman MD, Davies J, Ali MK, Flood D, Manne-Goehler J.
Yoo SGK, et al. Among authors: martins j.
Lancet Diabetes Endocrinol. 2026 Feb;14(2):105-108. doi: 10.1016/S2213-8587(25)00356-0.
Lancet Diabetes Endocrinol. 2026.
PMID: 41519598
Free PMC article.
No abstract available.